Development of boron nanocapsules for neutron capture therapy.

H. Nakamura,M. Ueno,H. Ban,K. Nakai,K. Tsuruta,Y. Kaneda,A. Matsumura

DOI: https://doi.org/10.1016/j.apradiso.2009.03.091

IF: 1.787

2009-07-01

Applied Radiation and Isotopes

Abstract:

What problem does this paper attempt to address?

Modes of Admission to Hospital: A Survey of Emergency Admissions to a General Medical Unit

A. Patel

DOI: https://doi.org/10.1136/BMJ.1.5743.281

1971-01-30

British Medical Journal

Abstract:In a survey of the modes of referral and disposal of “acute patients” to a general medical unit during the period 1 February 1968 to 31 July 1970 only 1,432 out of 3,455 were referred by general practitioners. There was a high incidence of self-referral to hospital, and this trend was on the increase. A large percentage of self-referred patients came from their homes, and 65-77% of these arrived by ambulance ordered by themselves.
Adeno-associated virus as a delivery vector for gene therapy of human diseases

Jiang-Hui Wang,Dominic J. Gessler,Wei Zhan,Thomas L. Gallagher,Guangping Gao

DOI: https://doi.org/10.1038/s41392-024-01780-w

IF: 39.3

2024-04-03

Signal Transduction and Targeted Therapy

Abstract:Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand has created challenges for the existing manufacturing methods. Seven rAAV-based gene therapy products have received regulatory approval, but there continue to be concerns about safely using high-dose viral therapies in humans, including immune responses and adverse effects such as genotoxicity, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity. In this review, we explore AAV biology with an emphasis on current vector engineering strategies and manufacturing technologies. We discuss how rAAVs are being employed in ongoing clinical trials for ocular, neurological, metabolic, hematological, neuromuscular, and cardiovascular diseases as well as cancers. We outline immune responses triggered by rAAV, address associated side effects, and discuss strategies to mitigate these reactions. We hope that discussing recent advancements and current challenges in the field will be a helpful guide for researchers and clinicians navigating the ever-evolving landscape of rAAV-based gene therapy.

biochemistry & molecular biology,cell biology
Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Xingyue Wang,Miao Wei,Rui Miao,Xiujing Hao,Min Li,Wenxin Wang,Zhonglei He

DOI: https://doi.org/10.1002/inmd.20240031

2024-01-01

Interdisciplinary Medicine

Abstract:AbstractAdeno‐Associated Virus (AAV) vectors have been found to have great potential in the field of gene therapy due to their unique properties. These nonpathogenic vectors exhibit high tissue specificity, low immunogenicity, and sustained gene expression, enhancing their efficacy for targeted delivery. This review explores the application of AAV vectors in gene therapy. It introduces the application and development of AAV in hemophilia and Duchenne Muscular Dystrophy. The review also highlights the use of AAV vectors in melanoma gene therapy, focusing on four key areas: cancer growth intervention, targeting cancer cells, mediating immune responses, and modulating key signaling pathways. However, despite its many advantages, rAAV faces significant challenges, including host immune responses and biological barriers that limit its effectiveness. Such complexities need to be addressed; therefore, this review also discusses the application of several polymers, such as hydrogels, nanoparticles, and solid scaffolds, in the controlled delivery of AAV.
Adeno-associated virus vector as a platform for gene therapy delivery

Dan Wang,Phillip W. L. Tai,Guangping Gao

DOI: https://doi.org/10.1038/s41573-019-0012-9

IF: 112.288

2019-02-01

Nature Reviews Drug Discovery

Abstract:Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.

pharmacology & pharmacy,biotechnology & applied microbiology
The clinical landscape for AAV gene therapies

Dmitry A. Kuzmin,Maria V. Shutova,Natalie R. Johnston,Owen P. Smith,Vasily V. Fedorin,Yury S. Kukushkin,Johannes C.M. van der Loo,Elaine C. Johnstone

DOI: https://doi.org/10.1038/d41573-021-00017-7

IF: 112.288

2021-01-25

Nature Reviews Drug Discovery

Abstract:Gene therapy using adeno-associated virus (AAV) as a vector has emerged as a novel therapeutic modality that has the potential to lead to substantial disease modification in many monogenic disorders, or perhaps even cures. Given the interest in the approach, which has been boosted by the recent approval of two AAV-based gene therapies by the US FDA, we have conducted a systematic review of the landscape of clinical trials of AAV-based gene therapies (see Supplementary Fig. 1 and Supplementary Table 1 for details). Here, we highlight the key trends and discuss the implications.

pharmacology & pharmacy,biotechnology & applied microbiology
AAV-based in vivo gene therapy for neurological disorders

Qinglan Ling,Jessica A. Herstine,Allison Bradbury,Steven J. Gray

DOI: https://doi.org/10.1038/s41573-023-00766-7

IF: 112.288

2023-09-02

Nature Reviews Drug Discovery

Abstract:Recent advancements in gene supplementation therapy are expanding the options for the treatment of neurological disorders. Among the available delivery vehicles, adeno-associated virus (AAV) is often the favoured vector. However, the results have been variable, with some trials dramatically altering the course of disease whereas others have shown negligible efficacy or even unforeseen toxicity. Unlike traditional drug development with small molecules, therapeutic profiles of AAV gene therapies are dependent on both the AAV capsid and the therapeutic transgene. In this rapidly evolving field, numerous clinical trials of gene supplementation for neurological disorders are ongoing. Knowledge is growing about factors that impact the translation of preclinical studies to humans, including the administration route, timing of treatment, immune responses and limitations of available model systems. The field is also developing potential solutions to mitigate adverse effects, including AAV capsid engineering and designs to regulate transgene expression. At the same time, preclinical research is addressing new frontiers of gene supplementation for neurological disorders, with a focus on mitochondrial and neurodevelopmental disorders. In this Review, we describe the current state of AAV-mediated neurological gene supplementation therapy, including critical factors for optimizing the safety and efficacy of treatments, as well as unmet needs in this field.

pharmacology & pharmacy,biotechnology & applied microbiology
Current Clinical Applications of In Vivo Gene Therapy with AAVs

Jerry R. Mendell,Samiah A. Al-Zaidy,Louise R. Rodino-Klapac,Kimberly Goodspeed,Steven J. Gray,Christine N. Kay,Sanford L. Boye,Shannon E. Boye,Lindsey A. George,Stephanie Salabarria,Manuela Corti,Barry J. Byrne,Jacques P. Tremblay

DOI: https://doi.org/10.1016/j.ymthe.2020.12.007

IF: 12.91

2021-02-01

Molecular Therapy

Abstract:Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. Since more than 30 years, hundreds of researchers have sustained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable and possibly curative clinical benefit with a single treatment.This review is limited to gene therapy using Adeno associated Virus (AAV) because the gene delivered by this vector do not integrate into the patient genome and has a low immunogenicity.There are now five treatments approved for commercialization and currently available, i.e., Luxtura, Zolgensma, the two CAR-T therapies (Yescarta and Kymriah) and Strimvelis (the gammaretrovirus approved for ADA-SCID in Europe). Dozens of other treatments are under clinical trials. The review article presents a broad overview of the field of therapy by in vivo gene transfer. We review gene therapy for neuromuscular disorders (spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), X-linked myotubular myopathy (XMTM), diseases of the central nervous system (including Alzheimer's Disease, Parkinson's Disease, Canavan Disease, Aromatic Amino Acid Decarboxylase Deficiency, Giant Axonal Neuropathy) and ocular disorders (Leber congenital amaurosis, age related macular degeneration (AMD), Choroideremia, Achromatopsia, Retinitis Pigmentosa and X-linked retinoschisis), the bleeding disorder hemophilia, and lysosomal storage disorders.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Engineering adeno-associated virus vectors for gene therapy

Chengwen Li,R. Jude Samulski

DOI: https://doi.org/10.1038/s41576-019-0205-4

IF: 59.581

2020-02-10

Nature Reviews Genetics

Abstract:Adeno-associated virus (AAV) vector-mediated gene delivery was recently approved for the treatment of inherited blindness and spinal muscular atrophy, and long-term therapeutic effects have been achieved for other rare diseases, including haemophilia and Duchenne muscular dystrophy. However, current research indicates that the genetic modification of AAV vectors may further facilitate the success of AAV gene therapy. Vector engineering can increase AAV transduction efficiency (by optimizing the transgene cassette), vector tropism (using capsid engineering) and the ability of the capsid and transgene to avoid the host immune response (by genetically modifying these components), as well as optimize the large-scale production of AAV.

genetics & heredity
Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Jalish M. Riyad,Thomas Weber

DOI: https://doi.org/10.1038/s41434-021-00243-z

2021-03-03

Gene Therapy

Abstract:In the last two decades, recombinant adeno-associated virus has emerged as the most popular gene therapy vector. Recently AAV gene therapy has been approved by the FDA for the treatment of two rare genetic disorders, namely the early childhood blindness disease Leber congenital amaurosis and spinal muscular atrophy (SMA). As is the case for the treatment of SMA, if the AAV vector must be administered systemically, very high vector doses are often required for therapeutic efficacy. But higher vector doses inevitably increase the risk of adverse events. The tragic death of three children in a clinical trial to treat X-linked myotubular myopathy with an AAV vector has thrown this limitation into sharp relief. Regardless of the precise cause(s) that led to the death of the two children, it is critical that we develop better AAV vectors to achieve therapeutic levels of expression with lower vector doses. To transduce successfully a target cell, AAV has to overcome both systemic as well as cellular roadblocks. In this review, we discuss some of the most prominent <i>cellular</i> roadblocks that AAV must get past to deliver successfully its therapeutic payload. We also highlight recent advancements in our knowledge of AAV biology that can potentially be harnessed to improve AAV vector performance and thereby make AAV gene therapy safer.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Valeria V. Kolesnik,Ruslan F. Nurtdinov,Ezekiel Sola Oloruntimehin,Alexander V. Karabelsky,Alexander S. Malogolovkin

DOI: https://doi.org/10.1002/ctm2.1607

IF: 8.554

2024-03-16

Clinical and Translational Medicine

Abstract:AAV‐based gene therapy are on increasing demand to cover the needs in the patient communities with inherited genetic disorders. Single AAV vectors delivering functional gene copy are the most popular approach in RnD pipeline. Multiple split vectors, inteins and trans‐splicing strategy so far underperform monovector AAV‐delivery. Neural networks guided by protein fitness data facilitate de novo protein design to fit into AAV capsid. Adeno‐associated virus (AAV)‐based therapies are recognized as one of the most potent next‐generation treatments for inherited and genetic diseases. However, several biological and technological aspects of AAV vectors remain a critical issue for their widespread clinical application. Among them, the limited capacity of the AAV genome significantly hinders the development of AAV‐based gene therapy. In this context, genetically modified transgenes compatible with AAV are opening up new opportunities for unlimited gene therapies for many genetic disorders. Recent advances in de novo protein design and remodelling are paving the way for new, more efficient and targeted gene therapeutics. Using computational and genetic tools, AAV expression cassette and transgenic DNA can be split, miniaturized, shuffled or created from scratch to mediate efficient gene transfer into targeted cells. In this review, we highlight recent advances in AAV‐based gene therapy with a focus on its use in translational research. We summarize recent research and development in gene therapy, with an emphasis on large transgenes (>4.8 kb) and optimizing strategies applied by biomedical companies in the research pipeline. We critically discuss the prospects for AAV‐based treatment and some emerging challenges. We anticipate that the continued development of novel computational tools will lead to rapid advances in basic gene therapy research and translational studies.

oncology,medicine, research & experimental
Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside

Liang Xu,Shun Yao,Yifan Evan Ding,Mengxiao Xie,Dingqi Feng,Pengfei Sha,Lu Tan,Fengfeng Bei,Yizheng Yao

DOI: https://doi.org/10.1186/s12967-024-05661-2

2024-09-27

Abstract:Recombinant adeno-associated viruses (rAAVs) have emerged as an attractive tool for gene delivery, and demonstrated tremendous promise in gene therapy and gene editing-therapeutic modalities with potential "one-and-done" treatment benefits compared to conventional drugs. Given their tropisms for the central nervous system (CNS) across various species including humans, rAAVs have been extensively investigated in both pre-clinical and clinical studies targeting neurodegenerative disease. However, major challenges remain in the application of rAAVs for CNS gene therapy, such as suboptimal vector design, low CNS transduction efficiency and specificity, and therapy-induced immunotoxicity. Therefore, continuing efforts are being made to optimize the rAAV vectors from their "core" genetic payloads to their "coat" or capsid structure. In this review, we describe current approaches for rAAV vector design tailored for transgene expression in the CNS, summarize the development of CNS-targeting AAV serotypes, and highlight recent advancements in AAV capsid engineering, aimed at generating a new generation of rAAVs with improved CNS tropism. Additionally, we discuss various administration routes for delivering rAAVs to the CNS and provide an overview of AAV-mediated gene therapies currently under investigation in clinical trials for the treatment of neurodegenerative diseases.
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview

Shaza S. Issa,Alisa A. Shaimardanova,Valeriya V. Solovyeva,Albert A. Rizvanov

DOI: https://doi.org/10.3390/cells12050785

IF: 6

2023-03-02

Cells

Abstract:Despite scientific discoveries in the field of gene and cell therapy, some diseases still have no effective treatment. Advances in genetic engineering methods have enabled the development of effective gene therapy methods for various diseases based on adeno-associated viruses (AAVs). Today, many AAV-based gene therapy medications are being investigated in preclinical and clinical trials, and new ones are appearing on the market. In this article, we present a review of AAV discovery, properties, different serotypes, and tropism, and a following detailed explanation of their uses in gene therapy for disease of different organs and systems.

cell biology
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Michael F. Naso,Brian Tomkowicz,William L. Perry,William R. Strohl

DOI: https://doi.org/10.1007/s40259-017-0234-5

IF: 7.744

2017-07-01

BioDrugs

Abstract:There has been a resurgence in gene therapy efforts that is partly fueled by the identification and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field, especially in clinical-stage experimental therapeutic strategies. The ability to generate recombinant AAV particles lacking any viral genes and containing DNA sequences of interest for various therapeutic applications has thus far proven to be one of the safest strategies for gene therapies. This review will provide an overview of some important factors to consider in the use of AAV as a vector for gene therapy.

oncology,pharmacology & pharmacy,immunology
Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Dezhuang Ye,Chinwendu Chukwu,Yaoheng Yang,Zhongtao Hu,Hong Chen

DOI: https://doi.org/10.1016/j.addr.2024.115363

Abstract:Adeno-associated virus (AAV) vectors have emerged as a promising tool in the development of gene therapies for various neurological diseases, including Alzheimer's disease and Parkinson's disease. However, the blood-brain barrier (BBB) poses a significant challenge to successfully delivering AAV vectors to the brain. Strategies that can overcome the BBB to improve the AAV delivery efficiency to the brain are essential to successful brain-targeted gene therapy. This review provides an overview of existing strategies employed for AAV delivery to the brain, including direct intraparenchymal injection, intra-cerebral spinal fluid injection, intranasal delivery, and intravenous injection of BBB-permeable AAVs. Focused ultrasound has emerged as a promising technology for the noninvasive and spatially targeted delivery of AAV administered by intravenous injection. This review also summarizes each strategy's current preclinical and clinical applications in treating neurological diseases. Moreover, this review includes a detailed discussion of the recent advances in the emerging focused ultrasound-mediated AAV delivery. Understanding the state-of-the-art of these gene delivery approaches is critical for future technology development to fulfill the great promise of AAV in neurological disease treatment.
Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

yuanshan liu,n siriwon,jennifer rohrs,peng wang

DOI: https://doi.org/10.2174/1381612821666150531171653

IF: 3.31

2015-01-01

Current Pharmaceutical Design

Abstract:Adeno-associated virus (AAV) vectors are promising human gene delivery vehicles due to their ability to establish long-term gene expression in a wide variety of target tissues; however, the broad native viral tropism raises concerns over the feasibility and safety of their systemic administration. To overcome this issue, much effort has been made to redirect AAVs toward specific tissues. This review presents several design strategies that have been applied to generate AAVs that target specific tissues and cells while inhibiting the transduction of non-target tissues. Multiple methods of vector capsid engineering have shown promise in vitro, including indirect targeting by adaptor systems and direct targeting by the insertion of antibodies or receptor-specific small peptide motifs. Other strategies, including creating mosaic or chimeric capsids and directed evolution, have also been used to successfully retarget AAV vectors. This research will further expand the clinical applications of AAV vectors by enhancing the control over tissue-specific gene delivery.
The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders

Kai Y Mak,Indu G Rajapaksha,Peter W Angus,Chandana B Herath

DOI: https://doi.org/10.2174/1566523217666170314141931

Abstract:Introduction: The first human adeno-associated virus (AAV) was originally discovered in 1960s as a contaminant of adenovirus stock preparation and thus it had not been of medical interest. Throughout the last three decades AAV has gained popularity to be used in gene therapy, mainly due to its replicative defectiveness and lack of pathogenicity in human. In addition, its ability to mediate stable and long-term expression in both non-dividing and dividing cells with specific tissue tropism makes AAV one of the most promising candidates for therapeutic gene transfer to treat many inherited as well as non-inherited disorders. Moreover, the use of AAV is not only restricted to overexpression of recombinant transgene, but also to over-express short hairpin RNA and microRNA to knockdown the expression of genes in targeted tissues. Discussion and conclusion: This review is organized into four parts. In the first part of the review, we discuss about the discovery and history of AAV, followed by detailed AAV biology such as virus genome, virus structure and its life cycle. In the second part of the review, the discussion is centred on the molecular mechanisms of AAV and tissue transduction, including receptor recognition and cell binding, endosomal entry, virus uncoating, nuclear entry and genome replication. Advantages and limitations of using AAV as a safe vehicle for gene delivery is also discussed. In the third part of the review, we discuss about the most commonly used AAV serotypes and variants isolated from human and non-human primates, focusing on their diverse tissue tropisms, transduction efficiency, immunological profiles and their applications in animal studies. Final part of the review focuses on the recent progress of in-vivo gene transfer using AAV for inherited and non-inherited diseases in both preclinical and clinical settings with a special emphasis on potential clinical applications of AAV in the field of liver disease.
Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system

Ana D Carneiro,David V Schaffer

DOI: https://doi.org/10.1016/j.cbpa.2024.102532

2024-09-28

Abstract:Harnessing adeno-associated virus (AAV) vectors for therapeutic gene delivery has emerged as a progressively promising strategy to treat disorders of both the central nervous system (CNS) and peripheral nervous system (PNS), and there are many ongoing clinical trials. However, unique physiological and molecular characteristics of the CNS and PNS pose obstacles to efficient vector delivery, ranging from the blood-brain barrier to the diverse nature of nervous system disorders. Engineering novel AAV capsids may help overcome these ongoing challenges and maximize therapeutic transgene delivery. This article discusses strategies for innovative AAV capsid development, highlighting recent advances. Notably, advances in next generation sequencing and machine learning have sparked new approaches for capsid investigation and engineering. Furthermore, we outline future directions and additional challenges in AAV-mediated gene therapy in the CNS and PNS.
Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

Yang Lu

DOI: https://doi.org/10.1089/154732804773099335

2004-07-09

Stem Cells and Development

Abstract:Recombinant adeno-associated virus (rAAV) is one of the most promising delivery vectors for gene therapy, due to its nonpathogenic property, nonimmunogenecity to host, and broad cell and tissue tropisms. This article summarizes the biological characteristics of AAV; the procedures to prepare, purify, and characterize the rAAV for gene therapy applications; and some of the clinical trials utilizing rAAV as delivery vehicles. Also discussed are the current efforts to modify rAAV to change its tropism, the application of different promoters to accommodate specific transgene expression, and the strategy to expand its capacity.

Biology,Medicine
Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Jingfeng Luo,Yuxuan Luo,Jihong Sun,Yurong Zhou,Yajing Zhang,Xiaoming Yang

DOI: https://doi.org/10.1016/j.canlet.2014.10.045

IF: 9.756

2015-01-01

Cancer Letters

Abstract:•The latest developments of AAV vectors were presented.•Latest issues of AAV-mediated gene therapy for cancers were summarized.•Up to date knowledge on the clinical trials of AAV-mediated gene therapy were reviewed.
Current developments of gene therapy in human diseases

Fanfei Liu,Ruiting Li,Zilin Zhu,Yang Yang,Fang Lu

DOI: https://doi.org/10.1002/mco2.645

2024-08-16

Abstract:Gene therapy has witnessed substantial advancements in recent years, becoming a constructive tactic for treating various human diseases. This review presents a comprehensive overview of these developments, with a focus on their diverse applications in different disease contexts. It explores the evolution of gene delivery systems, encompassing viral (like adeno-associated virus; AAV) and nonviral approaches, and evaluates their inherent strengths and limitations. Moreover, the review delves into the progress made in targeting specific tissues and cell types, spanning the eye, liver, muscles, and central nervous system, among others, using these gene technologies. This targeted approach is crucial in addressing a broad spectrum of genetic disorders, such as inherited lysosomal storage diseases, neurodegenerative disorders, and cardiovascular diseases. Recent clinical trials and successful outcomes in gene therapy, particularly those involving AAV and the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins, are highlighted, illuminating the transformative potentials of this approach in disease treatment. The review summarizes the current status of gene therapy, its prospects, and its capacity to significantly ameliorate patient outcomes and quality of life. By offering comprehensive analysis, this review provides invaluable insights for researchers, clinicians, and stakeholders, enriching the ongoing discourse on the trajectory of disease treatment.

Development of boron nanocapsules for neutron capture therapy.

Modes of Admission to Hospital: A Survey of Emergency Admissions to a General Medical Unit

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated virus vector as a platform for gene therapy delivery

The clinical landscape for AAV gene therapies

AAV-based in vivo gene therapy for neurological disorders

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Engineering adeno-associated virus vectors for gene therapy

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside

Various AAV Serotypes and Their Applications in Gene Therapy: An Overview

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders

Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system

Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Current developments of gene therapy in human diseases